Enhanced Specificity and Drug Delivery in Tumors by cRGD - Anchoring Thermosensitive Liposomes by Dicheva, B.M. (Bilyana) et al.
RESEARCH PAPER
Enhanced Specificity and Drug Delivery in Tumors by cRGD -
Anchoring Thermosensitive Liposomes
Bilyana M. Dicheva1,4 & Timo L. M. ten Hagen1 & Ann L. B. Seynhaeve1 & Mohamadreza Amin1,3 &
Alexander M. M. Eggermont1,2 & Gerben A. Koning1
Received: 18 March 2015 /Accepted: 24 June 2015 /Published online: 23 July 2015
# The Author(s) 2015
ABSTRACT
Purpose To develop RGD-targeted thermosensitive lipo-
somes with increased tumor retention, improving drug release
efficiency upon mild hyperthermia (HT) in both tumor and
angiogenic endothelial cells.
Methods Standard termosensitive liposomes (TSL) and TSL
containing a cyclic Arg-Gly-Asp (cRGD) pentapeptide with
the sequence Arg-Cys-D-Phe-Asp-Gly (RGDf[N-Met]C)
were synthetized, loaded with Dox and characterized.
Temperature- and time-dependent drug release profiles were
assessed by fluorometry. Intracellular Dox delivery was stud-
ied by flow cytometry and confocal microscopy. Cytotoxic
effect of TSL and RGD-TSL was studied on B16Bl6 melano-
ma, B16F10 melanoma and HUVEC. Intravital microscopy
was performed on B16Bl6 tumors implanted in dorsal-skin
fold window-bearing mice. Pharmacokinet ic and
biodistribution of Dox-TSL and Dox-RGD-TSL were follow-
ed in B16Bl6 tumor bearing mice upon normothermia or
initial hyperthermia conditions.
Results DLS and cryo-TEM revealed particle homogeneity
and size of around 85 nm. Doxorubicin loading efficiency was
>95%as assessed by spectrofluorometry. Flow cytometry and
confocal microscopy showed a specific uptake of RGD-TSL
by melanoma and endothelial cells when compared to TSL
and an increased doxorubicin delivery. High resolution intra-
vital microscopy demonstrated specific accumulation of
RGD-TSL to the tumor vasculature. Moreover, application
of hyperthermia resulted in massive drug release from RGD-
TSL. Biodistribution studies showed that initial hyperthermia
increases Dox uptake in tumors from TSL and RGD-TSL.
Conclusion RGD-TSL have potency to increase drug effica-
cy due to higher uptake by tumor and angiogenic endothelial
cells in combination with heat-triggered drug release.
KEY WORDS Doxorubicin . drug delivery . hyperthermia .
RGD - thermosensitive liposomes
ABBREVIATIONS
°C Degree celsius
DMEM Dulbecco modified eagle medium
Dox Doxorubicin
DPPC 1,2-dipalmitoyl-sn-glycero-3-
phosphatidylcholine
DSPC 1,2-distearoyl-sn-glycero-3-
phosphatidylcholine
DSPE-PEG2000 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000
Em. Emission
Ex. Excitation
FCS Fetal calf serum
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Fig. Figure
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HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid
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i.v. Intravenous
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NT Normothermia
PDI Polydisperisty index
S.c. Subcutaneous
SD Standard deviation
SEM Standard error
TEM Transmission electron microscopy
Tm Melting temperature
TSL Thermosensitive liposomes
INTRODUCTION
Nanoparticles, such as liposomes have passed different stages
of modifications in their design and nowadays are commonly
used in cancer chemotherapy (1). Stealth liposomal nanopar-
ticles of 100 nm are believed to accumulate passively in the
tumor due to the leaky tumor vasculature and related en-
hanced permeability and retention effect (2, 3). Liposomes
have contributed significantly to decrease toxic side effects
caused by free drug administration (4–6). However, tumor
accumulation of anticancer drugs using liposomes seemed
far from optimal to guarantee improvement in therapeutic
efficacy in clinical practice (4, 7). Low specificity of liposomes
and their high intrinsic stability limit therapeutic outcome.
Selectivity and efficacy can be achieved by decorating lipo-
somes with targeting ligands, while an external trigger, e.g.,
heat, can control liposomal drug release. In this study we
aimed at developing RGD-targeted thermosentitive lipo-
somes, which combine active targeting of tumors together
with a heat-triggered drug release function. These nanoparti-
cles contain multiple RGD peptides on their surface to
achieve tumor specificity and increased retention in tumors
and a thermosensitive bilayer for heat-triggered drug release.
In order to efficiently target tumor cells, liposomes first
need to extravasate from tumor vasculature and penetrate
the tumor tissue. However, the extravasation process is
usually heterogeneous and inefficient (3, 8). Targeting of
tumor vasculature rather than tumor cells has become a
promising approach in cancer therapy (9). In this case
several tumor pathophysiological barriers do not play a
role as endothelial cells are easily accessible to circulating
chemotherapeutic drugs and deep penetration into tumor
tissue is not necessary. Moreover, destruction of tumor
vessels leads to indirect killing of tumor cells, which
depend on their supply of oxygen and nutrients. Finally,
endothelial cells are genetically stable and therefore less
resistant to drug therapy (10). Besides vascular targeting,
those small liposomes may extravasate through the leaky
tumor vasculature and target tumor cells in addition (11).
Various vascular targets have been studied for anti-
vascular therapy of which αvβ3 integrins have been used most
often (12, 13). These integrins have been found to be
overexpressed on tumor vasculature, but also on some meta-
static melanoma cells (14, 15). The RGD (Arg-Gly-Asp) se-
quence is known to be a recognition motif for integrins such as
αvβ3 (16). Binding to either tumor or endothelial cells via
specific receptors may lead to internalization of liposomal
chemotherapy thereby bringing the drug closer to the nucleus.
The combination of targeting properties of this nanoparticle
with the heat-triggered release function might aid at releasing
the drug locally in the tumor. Besides triggering drug release,
hyperthermia (HT) is known to play a role in changing tumor
environment by increasing tumor blood flow, oxygenation
and vessel permeability (16–21).
An abundant amount of literature is available on
thermosensitive or targeted liposomes (22–25). However,
the combination of both strategies in one carrier is a
promising approach. In the present study we describe
the design, characterization and behavior of RGD-
targeted thermosensitive liposomes containing the chemo-
therapeutic drug doxorubicin in vitro and in vivo. These
liposomes were decorated with a novel and specific cyclic
Arg-Gly-Asp (cRGD) pentapeptide containing the se-
quence Arg-Cys-D-Phe-Asp-Gly (RGDf[N-Met]C) (26).
We tested the cytotoxic effect of those liposomes on mel-
anoma cell lines and endothelial cells. Extensive live cell
imaging was performed to study their intracellular fate
in vitro. In vivo, their affinity for tumors, drug release kinet-
ics and uptake were studied in dorsal skin fold window
chamber models implanted with melanoma B16Bl6 tu-
mors. Pharmacokinetics and biodistribution of Dox en-
capsulated in either TSL or RGD-TSL were investigated
in mice implanted with B16Bl6 tumors.
MATERIALS AND METHODS
Chemicals
The phosphol ipids 1,2-dipalmitoyl- sn-glycero-3-
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were
ordered from Lipoid (Ludwigshafen, Germany). 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-
1,3 benzoxadiazol-4-yl) (NBD-PE) and 1,2-Disteroyl-sn-
Glycero-3 -Phosphoe thano lamine-N-[Male imide
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(Polyethylene Glycol)2000] (Ammonium Salt) were purchased
from Avanti Polar Lipid Inc. Doxorubicin-HCl was from
Pharmachemie (Haarlem, The Netherlands). The RGDf[N-
Met]Cys was provided by Peptron, South Korea. Sodium
3′-[(1-phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-
6-nitro)benzene sulfonic acid hydrate (XTT) was purchased
from Sigma-Aldrich (Zwijndrecht, The Netherlands).
LysoTracker Red DND-99 and Dioctadecyl tetramethy-
lindotricarbocyanine perchlorate (DiD-C18(3)) were purchased
from Invitrogen.
Preparation of TSL
TSL and RGD-TSL were composed of DPPC:DSPC:DSPE-
PEG2000 in a molar ratio 70:25:5. RGD peptide was coupled
to mPEG in a molar ratio 1.1:1 (peptide:lipid) and coupling
efficiency was confirmed by MALDI analysis. For MALDI
analysis, all peptide samples were prepared as 0.001 M in
water. The matrix-assisted laser desorption/ionization
(MALDI) 2,5-dihyfroxy benzoic acid was prepared as
10 mg/mL in water. Ten microliter of sample and 90 uL of
matrix solution were mixed and 0.5 uL of this mixture was
spotted on an anchor chip plate and allowed to dry at ambient
temperatures. MALDI-TOFmass spectra were recorded on a
Bruker Ultraflex III mass spectrometer, Bremen, Germany
(27). Coupling of >95% was used for further liposome prep-
aration. Liposomes were prepared by lipid film hydration and
extrusion method (16). The lipids were dissolved in
chlorophorm and methanol (9:1 vol/vol). TSL used for con-
focal microscopy contained 0.3 mol% of NBD-PE or
0.3 mol% DiD in the lipid bilayer. TSL used for intravital
microscopy contained 0.3 mol% of DiD. The solvent was
subsequently evaporated in a rotary evaporator until homo-
geneous lipid film was formed. The lipid film was hydrated in
250 mM (NH4)2SO4 solution with a pH 5,0 at 60°C for
30 min. The spontaneously formed liposomes were extruded
subsequently 5 times through 100 nm, 5 times through 80 nm
and 5 times through 50 nm polycarbonate filter (thermo bar-
rel extruder at 60°C) and resulted in<100 nm TSL.
(NH4)2SO4 outside of liposomes was removed from liposomal
(NH4)2SO4 by a PD-10 to PD 10 (GE Healthcare, Bucking-
hamshire, UK), eluted with HEPES buffer, pH 7.4 (10 mM
HEPES, 135 mM NaCl). Size and polydispersity index (PDI)
were measured by dynamic light scattering using Zetasizer
Nano ZS (Malvern Instruments, Worcestershire, UK). Lipid
concentration was analysed by phosphate assay (27). After the
phosphate concentration was determined, doxorubicin was
loaded into the liposomes in 0,05:1 drug:lipid ratio (mol:mol)
at 38°C for 1 h. The liposomes were concentrated by ultra-
centrifugation for 2 h, 4°C, 106.000 ×g (Ti50.2 rotor). The
pellet was resuspended in HEPES buffer, pH 7.4 and left
overnight on slow rotation at 4°C. Then the liposomes were
passed through PD 10 column eluted with HEPES buffer,
pH 7.4 to remove free doxorubicin. Doxorubicin concentra-
tion was measured by spectrophotometer at Ex 480 nm and
loading efficiency (%) determined as [Dox/Lipid] after load-
ing/[Dox/Lipid] before loading x100.
TEM Cryo Imaging
Samples were prepared by adding a 2 μl droplet of liposome
suspension to a lacy carbon film and subsequently plunge-
freezing this sample into liquid ethane using a Vitrobot. An
amorphous (‘vitrified’) ice film which contains the particles of
interest was created. Cryo-TEM studies were performed using
a FEI TECNAI F30ST (300 kV, using a cryo-holder, keeping
the sample at –174°C during the studies). Imaging was done
in low-dose mode on a CCD camera (image size 1 × 1 k).
Stability at Physiological Conditions
Stability of TSL and RGD-TSLwas established by incubating
10 mM [lipid]) in pre-heated FCS (1:149 v/v) under stirring
and Dox release was measured for 1 h at 37°C. Samples
without incubation were considered as a blank (Io). TSL were
destroyed by adding 10% Triton X-100 (150:1 v/v) and con-
sidered as a positive control (I∞). Fluorescence was measured
by fluorometry at Ex. 479 nm / Em. 590 nm (Hitachi F-4500
Fluorescence Spectrophotometer). Dox release was deter-
mined as Dox (%)=(It−Io) / (I∞−Io)×100. Stability of lipo-
somes was calculated as 100 – Dox (%).
In Vitro Dox Release
Temperature-dependent Dox release kinetics from TSL and
RGD-TSL were performed by fluorometry upon incubating
the TSL samples (10 mM [lipid]) in pre-heated 90% fetal calf
serum (FCS) (1:9 v/v) at temperatures ranging between 37 and
45°C for 5 min in a thermal-shaker (Eppendorf
Thermomixer) at 300 rpm. Samples without incubation were
considered as a blank (Io). After incubation, the samples were
diluted in 10 mM Tris/NaCl 0.9%, pH 8.0 at 1:50 (v/v) and
Dox fluorescence was measured by fluorimetry at Ex. 479 nm
/ Em. 590 nm. Maximum Dox fluorescence (positive control)
(I∞) was achieved when incubating TSL suspension (10 mM
[lipid]) in 2% Triton X-100 in H2O for 30 min in a thermal
shaker at 55°C and 1400 rpm. The Dox release (%) was cal-
culated as Dox (%)=(It−Io) / (I∞−Io)×100. In vitro time-
dependent Dox release from TSL and RGD-TSL was mea-
sured at 42°C. TSL suspension (10 mM [lipid]) was mixed
with pre-heated FCS (1:149 v/v) under stirring and Dox re-
lease was measured over time (at 1, 2, 3, 4, 5, 30, 60min). TSL
samples without heating were considered as a blank. TSL
were destroyed by adding 10% Triton X-100 (150:1 v/v)
and considered as a positive control. The Dox release (%)
was calculated as described above.
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Cell Culture
Tumor cell lines B16Bl6 (murine melanoma) and B16F10
(metastatic murine melanoma) were cultured in a Dulbecco’s
Modified Eagles’ medium (Lonza, Belgium) containing 10%
FCS. Human umbilical vein endothelial cells (HUVECs) were
isolated in-house and cultured in Human Endothelial SFM
medium (Gibco, Invitrogen) enriched with 30% FCS. Cells
were passaged once a week using Trypsin (Sigma, Aldrich)
and maintained at 37°C, 5% CO2 in a humidified incubator.
All experiments were performed at a confluence of 80–90%.
In Vitro Dox-TSL Toxicity
B16Bl6, B16F10 and HUVEC cells were plated in 96 well
plates at concentration 12,000 cells/well for B16Bl6 and
B16F10 and 6000/well for HUVEC. The cells were allowed
to attach for 24 h at 37°C and after that incubated with var-
ious concentrations of free Dox, Dox-TSL or RGD-Dox-TSL
for 3 h at 37°C. After 3 h, liposomes were removed and cells
washed three times with medium with FCS. Plates were
placed at either normothermia (NT; 37°C) or hyperthermia
(HT; water bath at 42°C for 1 h) and then left in the incubator
at 37°C for additional 72 h. Cell survival was determined by
XTT assay. Electron coupling reagent N-methyl
dibenzopyrazine methylsulfate (1.25 mM in PBS; Sigma)
(100 μl) was mixed with 5 ml of XTT solution (1 mg/ml in
RPMI 1640) and each well was incubated with 50 μl of this
mixture for 1 h at 37°C. Afterwards, XTT conversion was
measured at 490 nm in a PerkinElmer Victor Wallac plate
reader (Perkin Elmer, Groningen, The Netherlands).
Flow Cytometry
Binding of TSL or RGD-TSL to B16Bl6, B16F10 and
HUVEC cells was assessed by flow cytometry (FACS) analysis.
1×105 cells in suspension were incubated for 3 h at 37°C with
400 nmol/ml TSL or RGD-TSL labelled with 0,3 mol%
NBD-PE. After incubation, cells were washed three times with
medium with FCS to remove unbound liposomes. Liposomal
NBD-PE fluorescence was determined at excitation and emis-
sion wavelengths of 470 and 530 nm by a BD FACScan
(Becton Dickinson, San Jose, CA, USA). Dead cells were la-
belled with propidiumiodide (PI) (Sigma, Aldrich) and 10,000
gated events were acquired per sample and samples were pre-
pared in triplicate. For Dox uptake FACS analysis, the same
amount of cells was incubated with 100 μM Dox for 3 h and
subsequently washed 3× with medium with FCS. Cells in
suspension were placed either at normothermia (37°C) or hy-
perthermia (42°C) for 1 h. Dox fluorescence was determined
at excitation and emission wavelengths of 488 and 585 nm,
respectively. As a dead cell marker, Sytox Green (Invitrogen)
was used. Data was analysed with FlowJo software.
Experiments were performed three times with three different
batches of liposomes.
Live Cell Confocal Microscopy
B16Bl6, B16F10 or HUVEC cells were seeded at the same
concentrations as for fluorescent microscopy in cell culture
chambers containing a cover glass insert coated with 0.1%
gelatine. Cells were allowed to recover for 24 h. After 24 h,
cells were incubated with 400 nmol/ml NBD-PE labelled
TSL or RGD-TSL for 3 h at 37°C and for 30 min with
lysotracker (LysoTracker® Red DND-99). After incubation,
cells were washed three times with DMEM (B16Bl6 and
B16F10) orHUVECmedium (HUVEC). Cells were analyzed
on a Zeiss LSM 510 META confocal laser scanning micro-
scope. NBD-PE fluorescence was detected by 513 nm argon
laser and lysotracker was monitored by a 543 nm Helium –
Neon laser. For Dox release experiments, cells were incubated
with NBD-PE or DiD labelled Dox-TSL or RGD-Dox-TSL
for 3 h at 37°C and after that washed three times with medi-
um with FCS. Dox release was followed in time for 1 h at
42°C (40 × objective lens, 2,5 μm pinhole) and its fluores-
cence was detected by a 543 nm Helium –Neon laser. Images
of 1024×1024 pixels were analyzed using Zeiss LSM image
software (Zeiss, Germany).
Animal Models
B16Bl6 (murine melanoma) cells were cultured in DMEM
mediumwith 10%FCS. Tenmillion tumor cells were injected
subcutaneously in the flanks of C57Bl6 mice and bulk tumors
of 10 mm in diameter were used for transplantation into
C57Bl6, expressing an eNOS-tag-GFP fusion protein consti-
tutively in their vascular endothelium. Tumor pieces were
implanted in a dorsal skin flap window chamber for intravital
imaging. Bulk mice were housed at 20–22°C, humidity of 50–
60%. Window chamber-bearing mice were used for experi-
ments after 8–12 days of tumor implantation when tumor size
reached 4–6 mm in diameter. These mice were housed in an
incubator room with a humidity of 70% and temperature of
30–32°C. All mice were fed a standard laboratory diet ad
libitum (Hope Farms Woerden, the Netherlands). Mice
weighing 20–25 g were used for experiments. All animal ex-
periments were performed in compliance with protocols ap-
proved by the committee on Animal Research of the Erasmus
MC, Rotterdam, The Netherlands.
Intravital Microscopy for Dox Release
upon Hyperthermia and Uptake by Tumor
and Angiogenic Endothelial Cells
Liposome binding to tumor vasculature and their clearance
from circulation was analysed by intravital microscopy after
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injection of DiD-labelled TSL or RGD-TSL and followed up
to 24 or 5 h respectively. In order to evaluate Dox release
during hyperthermia and its uptake by tumor vascular endo-
thelial cells and tumor cells, DiD-labelled Dox-TSL or RGD-
Dox-TSL were injected i.v. through the penile or tail vein at a
dose of 5 mg/kgDox. Both formulations were allowed to cir-
culate for 5 h at body temperature in order to be able to bind
to vascular angiogenic endothelial cells or tumor cells and
observed by confocal microscopy (Zeiss LSM 510 META).
After 5 h of circulation, tumor was heated at 42°C for 1 h
and Dox release and uptake was detected as above (20× ob-
jective lens). Regions of interest were selected before, during
and in the end of the hyperthermia treatment. Images of
1024×1024 pixels were analyzed using Zeiss LSM image soft-
ware (Zeiss, Germany).
In Vivo Dox Quantification
The integrated density (IntDen) from the red channel
(obtained after setting a threshold) representing released
doxorubicin at 42°C into mice injected with either
RGD-Dox-TSL or Dox-TSL was quantified from 13 po-
sitions from each group, which were obtained from three
mice. The data are presented as an average of IntDen of
all the positions of each mouse. The data was analyzed
by Image J software. When DiD quantified, 3–6 posi-
tions were used per mouse obtained from three mice
from each group. The data are presented as an average
of IntDen of all the positions of each mouse.
Pharmacokinetic and Biodistribution of Dox-TSL
and Dox-RGD-TSL
Pharmacokinetic and biodistribution of Dox-TSL and Dox-
RGD-TSL was followed in B16Bl6 tumor bearing mice upon
NT or initial HT conditions. At NT condition, mice were
injected with 3 mg/kg Dox and blood sampling was per-
formed at 0.1;1;2;4;6 and 24 h and organs were collected
24 h after liposome injection. At HT condition, tumors were
first preheated for 1 h at 41°C and then cooled down for
15 min, in order to facilitate liposome extravasation. Then,
liposomes were injected at 3 mg/kg Dox and blood samples
were collected up to 24 h (0.1;1;2;6;24 h), after which the
organs were removed. The Dox concentration in the blood
and organs was analyzed by HPLC and calculated as%
injected dose/g tissue (%ID/g). Six mice were used per each
group.
Statistics
In vivo drug release was analyzed by Mann-Whitney test and
results with p-value≤0.05 were considered statistically
significant.
RESULTS
Liposome Characterization
RGD-TSL and TSL consisted of the phospholipids DPPC,
DSPC, DSPE-PEG2000 in a molar ratio (70:25:5). In the
RGD-TSL formulation, RGD peptide was coupled to
mPEG2000 and its coupling efficiency was analyzed by
MALDI (Fig. 1), after which it was mixed with all the lipids
in a molar ratio (70:25:5). Both formulations were prepared
by lipid film hydration and extrusion method (28). Dox was
loaded into the liposomes after extrusion by (NH4)2SO4 load-
ing method (29). Liposomes were characterized by measuring
size, polydisperity index (pdI), encapsulation efficiency and
stability. All liposomes were ~85 nm after extrusion and with
a pdI<0.1. After Dox loading, liposomes retained their small
size and a low pdI. Encapsulation efficiency of both formula-
tions was >95%. Liposomes were comparably stable after 1 h
of incubation at 37°C in 99% FCS. TSL contained 92%±1.8
of the entrapped Dox after 1 h at 37°C whereas RGD-TSL
contained 85%±2.3 (data not shown).
Temperature- and Time-Dependent Dox Release
In order to test whether liposomes are thermosensitive, their
temperature- and time-dependent drug release profiles were
determined (Fig. 2a and b). According to the temperature-
dependent release kinetics (A), which was performed at vary-
ing temperatures (37–45°C), both formulations were
thermosensitive showing an increasing drug release with in-
creasing temperature. The formulations were stable at physi-
ological temperatures (37–38°C) in 5 min and started to re-
lease their drug payload slightly at 39°C. The maximum drug
release from TSL in 5 min was observed at 42°C (~85%),
whereas for RGD-TSL it was at 43–44°C (~80%), after which
temperatures the drug release declined as seen before (21).
Time-dependent release profile at a constant temperature
of 42°C for 1 h was similar for both formulations (Fig. 2b).
RGD-TSL and TSL rapidly released Dox in the first minute
and released >90% of the encapsulated Dox in 1 h.
Active loading of Dox into RGD-TSL and TSL by ammo-
nium sulphate gradient method resulted in an abundant
amount of intraliposomal Dox crystals, which were well visu-
alized by TEM cryo imaging in both formulations (Fig. 2c).
RGD-TSL Demonstrate Higher Uptake by Tumor
and Endothelial Cells than Non-targeted TSL
In order to test whether RGD coupling to liposomes increases
liposomal uptake into tumor and endothelial cells, confocal
microscopy and FACS analysis on melanoma B16Bl6 and
B16F10 cells and HUVEC with NBD-PE labelled TSL or
RGD-TSL was performed. Confocal microscopy on
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B16Bl6, B16F10 and HUVEC demonstrated that RGD-TSL
are more abundantly taken up by the tumor cells and
HUVEC compared to TSL (Fig. 3a). The 3 h incubation
period at 37°C followed by a washing step for removal of
unbound liposomes revealed that the RGD modification of
TSL led to a preferential binding and uptake by all the cell
Fig. 1 MALDI-TOFF spectra of the free peptide RGD (a), the free lipid (b upper panel) and the coupled RGD to mPEG in lipopeptide (b lower panel).
Fig. 2 Temperature- (a) and time- (b) dependent Dox release kinetics from RGD-TSL and TSL. Temperature-dependent drug release profile was performed in
temperatures between 37 and 45°C for 5 min in 90% FCS. Time-dependent release was carried for 1 h at 42°C in 99,7% FCS. Mean of three independent
experiments with three different batches of liposomes. TEM-cryo imaging (c) of Dox-TSL and Dox-RGD-TSL. Bar, 100 nm.
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lines. This was confirmed also by FACS analysis (Fig. 3b). In
order to measure Dox delivery, FACS analysis was performed
in B16Bl6, B16F10 and HUVEC after 1 h (C) or 3 h (D) of
incubation with Dox-TSL or Dox-RGD-TSL followed by 1 h
of HT at 42°C. The amount of Dox delivered fromRGD-TSL
at NT was higher than TSL in all cell lines and this amount
further increased after 3 h of incubation.WhenHTwas applied
to the cells after 1 h of incubation at 37°C, there was an increase
in Dox release and uptake in all cell lines. HT trigger did not
further increase the delivered Dox to B16Bl6 and B16F10 cells
after 3 h of incubation. Only in HUVECs there was an in-
creased delivery of Dox upon HT after 3 h of incubation.
Uptake of RGD-TSL in Lysosomes and Intracellular,
HT-Triggered Dox Release from RGD-TSL in Tumor
and Endothelial Cells
The intracellular localization of liposomes was studied by live
cell imaging in B16Bl6, B16F10 and HUVEC (Fig. 4a). Cells
were incubated with NBD-PE labelled (green) RGD-TSL and
lysotracker (red, to stain lysosomes) for 3 h at 37°C, after
which the unbound liposomes were removed by washing.
B16Bl6 and B16F10 were able to localize the RGD-TSL in
the cytoplasm after 3 h of incubation and those liposomes
were colocalized with the red lysotracker, seen as yellow fluo-
rescence signal (white arrows). Still, there were some RGD-
TSL (green fluorescence spots), which were not concentrated
in the acidic compartments (blue arrows). By contrast, in
HUVEC sequestering of RGD-TSL in the lysosomes oc-
curred at a slower pace. After 3 h of incubation at 37°C,
liposomes and lysotracker were observed as green and red
separated fluorescence signals, showing no entrapment of
the liposomes in the lysosomes. However, when cells were
followed for a prolonged period, colocalization (in yellow)
started to be visible. After 7 h of incubation, there was an
abundant amount of RGD-TSL localized in the lysosomes
but also some non-entrapped liposomes in lysosomes could
be observed.
To prove that Dox-RGD-TSL deliver the encapsulated
drug intracellular, live cell imaging on B16Bl6, B16F10 and
Fig. 3 Confocal live-cell imaging for preferential uptake of RGD-TSL compared to TSL into B16Bl6, B16F10 and HUVEC cells after 3 h of incubation at 37°C (a).
Unbound liposomes were removed by washing. Scale bar applies for all images, 10 μm. Intracellular NBD-PE fluorescent intensity represented as mean
fluorescent intensity (MFI) in melanoma B16Bl6, B16F10 cells and HUVEC (b) treated with either TSL or RGD-TSL for 3 h at 37°C. Unbound liposomes were
removed by washing. As unstained cells are used cells which were not incubated with liposomes. c and d. Intracellular Dox uptake represented as MFI in
melanoma B16Bl6, B16F10 cells and HUVEC after 1 h (c) or 3 h (d) of incubation at 37°C, washing of unbound liposomes, followed by 1 h of HTat 42°C.
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HUVEC was performed using DiD labelled Dox-RGD-TSL
and green lysotracker (Fig. 4b). Removing the unbound lipo-
somes 3 h after incubation at 37°C resulted in some doxoru-
bicin release inside of all cell lines, most probably due to
processing of liposomes by the cells in this time frame. The
released Dox localized mainly in the cell nuclei but could also
be observed in the cytoplasm. The application of HT for 1 h
triggered additional Dox release, seen as increased red
Fig. 4 (a). Confocal microscopy on melanoma B16Bl6 and B16F10 cells and HUVEC incubated with NBD-PE (green) labelled RGD-TSL for 3 h at 37°C and
lysotracker (red). Unbound liposomes were removed by washing 3× with medium without FCS. After washing, B16Bl6 and B16F10 were immediately imaged
at 37°C, whereas HUVECwere followed up to 7 h. Internalized liposomes in the cytosol can be observed in all the cell lines (white arrows). Non-internalized in the
lysosomes liposomes were also visible (blue arrows). B16Bl6 and B16 internalized liposomes immediately in the lysosomes after the 3 h of incubation period (yellow
colocalization of green liposomes and red lysotracker), whereas this process happened in HUVEC after 7 h. Images were taken by confocal microscope (40×,
2,5 μm pinhole, 2× zoom). Scale bar applies for all images, 20 μm. (b). Doxorubicin release (red) from DiD-labelled RGD-TSL (purple) in B16Bl6, B16F10 and
HUVEC upon HT trigger. Cells were incubated with 50 μM Dox for 3 h at 37°C, after which cells were washed 3× with medium without FCS. Images were
taken right after this incubation at 37°C. Then, HTat 42°C for 1 h was applied and images in the end of the HT treatment were recorded. Images were taken by
confocal microscope. Scale bar applies for all images, 50 μm. (c). Colocalization of RGD-TSL (purple) with lysotracker (green) and Dox release (red) in the
lysosomes. Scale bar applies for all images, 10 μm.
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fluorescence signal intracellularly. In B16Bl6 and B16F10, the
Dox delivery upon HT treatment was predominantly nuclear,
whereas in HUVEC it was cytoplasmic (Fig. 4b and c). In
accordance with Fig. 4a, DiD-labeled RGD-TSL (purple) also
localized in lysosomes (green) to some extent. Non-colocalized
liposomes with lysosomes could also be observed. Interesting-
ly, the released cytoplasmic Dox upon HT colocalized with
the green lysotracker, which indicates Dox release fromRGD-
TSL also occurs in acidic compartments in the cytosol (Fig. 4b
and c).
Cytotoxicity of Dox Encapsulated in TSL and RGD-TSL
upon NTand HT
Incubation of B16Bl6,B16F10 and HUVEC cells for 3 h with
Dox-TSL or Dox-RGD-TSL showed no differences in cell
toxicity determined 72 h later as seen in Fig. 5 and Table 1.
Application of HT for 1 h at 42°C after 3 h of liposomes
incubation could not further improve cytotoxicity impact
72 h later in B16F10 and HUVEC but only to some extent
in B16Bl6 cells. Free Dox demonstrated the highest cytotox-
icity on all the cell lines because it is rapidly taken up by the
cells in its free form.
Binding to- and Extravasation from Tumor Vasculature
of TSL and RGD-TSL
In order to proof that RGD-TSL target angiogenic endothelial
cells in vivo, intravital microscopy in B16Bl6 window chamber
bearingmice was performed. To visualize circulating liposomes
in the blood stream, liposomes were labelled with DiD (purple).
In these mice tumor vasculature is visualized by the constitutive
expression of a GFP-eNOS-tag fusion protein in endothelial
cells (Fig. 6). Twenty minutes after injection of RGD-TSL, next
to circulating liposomes in the lumen of the blood vessels,
bound RGD-TSL could be observed (Fig. 6a yellow arrows).
These liposomes can be visualized as patchy fluorescent spots
on the vessel walls. Besides bound liposomes to the angiogenic
endothelial cells, extravasated liposomes from tumor vascula-
ture are visible already 20 min after injection (white arrows).
They are visible as diffuse purple fluorescence outside of the
green blood vessels. Binding continued in time and was pro-
nounced 24 h after injection. In contrast, using DiD-labeled
TSL, no binding to tumor vasculature was detected after 5 h
of circulation. In the last time point (24 h), only extravasated
TSL were visible (Fig. 6a, right panel).
Liposome clearance from circulation during the 5 h
targeting phase and Dox triggered release upon HT was fur-
ther evaluated by intravital microscopy in B16Bl6 window
chamber bearing mice (Fig. 6b). Liposome clearance was ob-
served already 2 h after injection by decrease in DiD fluores-
cence signal from both RGD-TSL and TSL. Clearance of
liposomes continued in time up to 5 h (Fig. 6b and c). However,
RGD-TSL bound to tumor vasculature were visible already
5 min after injection, whereas this was not observed for TSL
even after 5 h of circulation, which is in accordance with Fig. 6a.
HT trigger at 42°C for 1 h did not seem to cause any additional
clearance neither of RGD-TSL or TSL. Upon HT, TSL could
be observed extravasated from the tumor vasculature (white
arrows), a process which is known to be heterogeneous within
the tumor. This is in accordance with the quantification of the
images, showing an increase of the TSL signal upon HT, which
is most probably due to extravasation. However, there was no
increase of the RGD-TSL levels upon HT (Fig. 6c).
In VivoDox Release upon HTand Dox Uptake by Tumor
and Endothelial Cells
In order to understand whether RGD-TSL release Dox in vivo
upon HT treatment and to follow Dox distribution in the
tumor, intravital microscopy was performed. Circulation of
TSL and RGD-TSL for 5 h in the blood stream did not cause
any premature release of Dox (data not shown). However,
when HT at 42°C was applied, immediate Dox release (red)
was observed fromTSL (Fig. 7a) and RGD-TSL (Fig 7b). Dox
from both formulations was released first intravascularly from
the circulating DiD-labelled liposomes (purple), after which it
was gradually taken up by endothelial cells and tumor cells
surrounding the blood vessels (Fig. 7d and supporting
information, video 1). The Dox uptake in the both treatment
groups increased in time and was maximal after 1 h of HT,
when also the lumen of the blood vessels was cleared from
Dox. Quantification of the images showed that the amount
of delivered Dox to the tumor from RGD-TSL was 1.7 fold
higher than from TSL (Fig. 7c). However, this difference was
not statistically significant (p-value=0.8).
To follow up Dox clearance from circulation, its distribu-
tion in healthy organs and tumors and to be able to quantify
Dox concentrations in tumors and organs, the pharmacoki-
netic and biodistribution profiles of Dox in TSL or RGD-TSL
were studied (Fig. 8) under NT or initail HT conditions. At
NT condition (Fig. 8a and c), Dox from both formulations
seemed to clear from circulation quite fast in the first 1 h, as
it was faster for RGD-TSL than for TSL (27% v/s 52% re-
maining Dox respectively). After 2 h of liposome circulation,
the trend was the same showing lower remaining Dox from
RGD-TSL than from TSL (10% v/s 20% respectively). At
later time points (4,6,24 h) there was barely any Dox present
in circulation from TSL and RGD-TSL. The application of
initial HT (Fig. 8b) seemed to increase the presence of Dox
from RGD-TSL in circulation at 1 h time point, after which
its clearance was the same as at NT conditions. Besides, upon
initial HT conditions, clearance of Dox from TSL and RGD-
TSL was similar. Considering the biodistribution of Dox
(Fig. 8c and d), at both NT and HT conditions, there was a
significant uptake of Dox from both formulations in the spleen
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as it was higher for Dox from RGD-TSL than TSL (11.3
respectively v/s 8.3% ID/g at NT; and 11 v/s 6% ID/g at
HT). Similar high Dox accumulation in the kidney was ob-
served from both formulations. Dox accumulated in the liver
was similar for RGD-TSL and TSL under NT (3.9%ID/g
respectively v/s 2.7%ID/g). The higher Dox uptake in spleen
and liver from RGD-TSL is due to most probably
opsonization of RGD-TSL by proteins in these organs. There
was a minimal uptake of Dox fromTSL andRGD-TSL in the
heart, lungs and muscle upon NT and HT. No Dox was
Fig. 5 Cytotoxicity of Dox-TSL
and Dox-RGD-TSL either at 37 or
42°C in B16Bl6 (a), B16F10 (b) and
HUVEC (c) determined 72 h after
liposome incubation.
Table 1 *IC 50 Values in μM Dox of B16Bl6 Murine Melanoma, B16F10 Murine Melanoma and Endothelial Cell (HUVEC) Treated with Free Dox or Dox
Formulated in TSL or RGD-TSL for 1 h at 37°C. After removal of unbound liposomes, cells were subjected toHTat 42°C for another 1 h (in blue) or NT (in black)
as a control
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detected in the brain from neither of the formulations. At NT,
the tumor uptake of Dox was similar for both formulations.
Application of initial HT for 1 h at 41°C was able to cause~
3.7 fold increase of Dox delivery to the tumor from RGD-
TSL (1.6 v/s 6% ID/g) and~2.3 fold increased Dox amount
to the tumor from TSL (1.7 v/s 4% ID/g). The amount of
Dox delivered to the tumor upon initial HT conditions from
RGD-TSL was not significantly different from Dox delivered
from TSL (p-value 0.1).
DISCUSSION
Nanoparticles, such as liposomes have been successfully de-
signed and used in treatment of various types of cancer (30).
Although modifications to these nanocarriers contributed to
decreased drug-related side effects, their high stability (31–33)
and limited tumor localization (34) prevent the desired in-
crease in therapeutic outcome (4, 7). Forcing encapsulated
drug to leave the liposome, as is achieved with TSL exposed
to hyperthermia, leads to an enhanced drug release locally in
the tumor (35–37). Also, application of an external trigger
such as HT, can promote liposome extravasation from tumor
vasculature and increase their accumulation locally in the tu-
mor area (18–20, 38). When combined, this interstitial release
approach relies primarily onHT-augmented liposome extrav-
asation followed by heat-triggered drug release (39). More
directly, improved drug accumulation is observed with the
intravascular release approach, for instance with lysolipid-
thermosensitive liposomes (40). Next to the use of an external
Fig. 6 (a). Binding of DiD-labeled
RGD-TSL (purple) to tumor
vasculature (green) of B16Bl6
window chamber bearing mice.
Binding of liposomes to tumor
endothelial cells started 20 min after
injection and was followed in time
up to 24 h. Representative images
from intravital microscopy were
selected. Scale bar applies to all
images, 50 μm. (b). RGD-TSL and
TSL appearance (DiD, in purple) in
tumor vasculature (green) during 5 h
at NT in B16Bl6 window bearing
mice (Fig B left panels) and upon
subsequent HTat 42°C for 1 h
(Fig. 5b right panels). DiD-labelled
RGD-TSL or TSL were injected i.v,
after which they were allowed to
circulate in blood stream at NT for
5 h in order to allow binding of
RGD-TSL to angiogenic endothelial
cells. Thereafter, HTat 42°C for 1 h
was applied to promote
extravasation of RGD-TSL and TSL.
Scale bar applies to all images
50 μm. (c). In vivo quantification of
DiD liposomal fluorescence before
and during 1 h of HT, presented as
integrated density (IntDen) in time,
see Materials and methods for
details.
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trigger for controlling drug release, decorating liposomes with
targeting ligands specific for the tumor cells or vasculature can
also increase the liposomal drug efficacy. We have recently
developed cationic thermosensitive liposomes, a nanoparticle
Fig. 7 Dox release upon HT treatment from TSL (a) and RGD-TSL (b) in B16Bl6 window chamber bearing mice. Mice were injected with 5 mg/kg Dox in
DiD-labelled (purple) TSL or RGD-TSL. After 5 h of liposome circulation, a temperature of 42°C for 1 h was applied to trigger Dox release. Representative images
were taken from the beginning of the HT treatment up to 1 h. (c). In vivo quantification of Dox released from RGD-TSL or TSL 1 h after HT treatment, presented
as integrated density (IntDen), see materials and methods. (d). Dox uptake in endothelial cells (green) and tumor cells from RGD-TSL after 1 h of HT treatment.
Scale bar applies for all images, 50 μm.
Fig. 8 Pharmacokinetics (a and b)
and biodistribution (c and d) of
Dox-TSL and Dox-RGD-TSL in
B16BL6 tumor bearing mice upon
NTor initial HTconditions. A,C. At
NTcondition, mice were injected
with 3 mg/kg Dox and blood
sampling was performed at the
indicated time points and organs
collected 24 h after liposomes
injection. At HTcondition (b and d),
tumors in mice were preheated for
1 h at 41°C and cooled down for
15 min, in order to allow for
liposome extravasation. Then,
liposomes were injected at 3 mg/kg
Dox and blood samples were
collected up to 24 h, after which the
organs were removed. The Dox
concentration in the blood and
organs was analyzed by HPLC.
Drug Delivery to Tumors by RGD-Targeted Thermosensitive Liposomes 3873
combining targeting and triggered release properties in one
carrier (41, 42) and redesigned it in ordered to achieve a
pharmaceutically stable formulation. In the present study,
we report on the development of TSL decorated with another
targeting ligand, cRGD (RGDf[N-Met]C, which is specific for
integrins overexpressed on both tumor vasculature and tumor
cells.
Engrafting of TSL with cRGD did not cause significant
changes in the pharmaceutical properties of the formulation.
Dox-TSL and Dox-RGD-TSL were similar in size, pdI, Dox
encapsulation and Dox release kinetics. This is in accordance
with Al-Ahmady et al. using monoclonal antibody-targeted
thermosensitive liposomes showing that traditional
thermosensitive liposomes maintain their physicochemical
and thermal properties when conjugated to the monoclonal
antibody (43). Both formulations showed to be stable at tem-
peratures up to 38°C, slightly released Dox at 39°C and at
42°C released >90% of the encapsulated Dox in 1 h,charac-
teristics favorable for use in clinical settings. In accordance
with Kim et al. (44) and Al-Ahmady et al. (43) there was a
preferential uptake of RGD-TSL by both melanoma and en-
dothelial cells, which was confirmed by FACS analysis and
confocal microscopy (Fig. 3a and b). The specificity of
RGD-TSL for the tested cell lines contributed to an increased
Dox delivery to all the cell lines at both NT and HT condi-
tions (Fig. 3c and d). After 1 h of incubation at NT with either
TSL or RGD-TSL, there was an increased Dox uptake by all
the cell lines from RGD-TSL. HT additionally triggered the
drug release and uptake fromTSL and RGD-TSL, which was
higher for RGD-TSL than TSL. In accordance with Al-
Ahmady et al. (43), the longer incubation period of 3 h at
37°C led to an increased Dox uptake in the cell lines and
was higher again for RGD-TSL. However, the subsequent
HT trigger did not change the drug uptake in the melanoma
cell lines, which is most likely due to the fact that in the 3 h
period the cells are able to degrade the liposomes themselves
preventing an additional release upon HT. Only an increase
in drug uptake upon HT after 3 h of incubation was observed
with HUVECs, which might be due to the fact that these cells
take longer time to entrap liposomes in acidic compartments
in the cytosol (Fig. 4a). In contrast, B16Bl6 and B16F10 were
able to process endocytosed RGD-TSL in a faster manner.
Using confocal microscopy, we demonstrated that HT was
able to trigger drug release and uptake in vitro in melanoma
and endothelial cells. After 3 h of incubation of the cells at
37°C with Dox-RGD-TSL, there was a premature drug re-
lease and uptake most likely due to cellular processing of the
drug at this time point. However, HT additionally increased
Dox delivery in all the cell lines and was mostly nuclear for
melanoma cells and both nuclear and cytoplasmic for
HUVEC (Fig. 4b and c), which is in accordance with Kim
et al. (44). There was no difference in cytotoxicity of Dox-TSL
and Dox-RGD-TSL to any of the cell lines at NT conditions.
A HT trigger could not further increase the cytotoxicity of
Dox-RGD-TSL in B16F10 and HUVEC but only in B16Bl6.
This is likely due to the nature of the assay in which cytotox-
icity is measured 72 h after nanoparticle incubation and heat
treatment. During the remaining 72 h also non-heat triggered
RGD-TSL will release their Dox contents intracellularly due
to nanoparticle processing, causing cellular cytotoxicity.
The 5 h targeting phase did not show any premature Dox
release from neither RGD-TSL or TSL (data not shown),
which is in accordance with other targeted TSL (42). During
this phase, RGD-TSL bound to tumor endothelial cells already
20min after liposome injection and were observed bound up to
24 h. In contrast, TSL did not bind to tumor vasculature and
were mostly extravasated 24 h after injection (Fig. 6a), which
confirmed the targeting properties of RGD-TSL. Liposomes
were cleared from circulation gradually in 5 h, shown by intra-
vital microscopy and image quantification. The application of
HT could increase TSL extravasation starting at 30 min of HT
and increasing up to 1 h, which is in accordance with Li et al.
(20) and Dicheva et al. (42) (Fig. 6b and c).
HT at 42°C could trigger a massive Dox release from both
RGD-TSL and TSL. Release started already 5 min after heat
trigger and increased up to 1 h (Fig. 7a). Image quantification
from numerous positions in the tumor in several mice demon-
strated that due to the RGD-TSL specificity for the tumor,
these liposomes delivered 1.7 fold higher amount of doxoru-
bicin than TSL (Fig. 7c). However, this difference was not
statistically significant. Additionally, hyperthermia triggered
release of Dox and Dox was subsequently taken up by both
and angiogenic endothelial cells, which proves the dual
targeting approach (Fig. 7d).
The pharmacokinetic behavior of Dox-TSL and Dox-RGD-
TSL was investigated with or without initial HT. Initial HT was
used to increase liposome extravasation. Dox from RGD-TSL
was cleared faster from circulation than Dox from TSL under
NT. This observation might show that targeting influenced Dox
clearance. However, upon HT conditions, Dox clearance from
circulation from the two formulations was similar.
Biodistribution studies showed that the highest uptake of
Dox-TSL and Dox-RGD-TSL was in the spleen and the kid-
neys followed by the liver (Fig. 8c and d). The high spleen and
liver uptake are due to the fact that these organs are part of the
mononuclear phagocyte system (MPS), which is responsible for
filtering out of liposomes from the blood circulation (45). There
was no explanation why kidneys had an increased Dox uptake
at both NT and HT conditions. As expected, there was a little
Dox uptake from the two formulations under NT and HT in
heart and lungs and no uptake in brain and the leg muscle close
to the heated tumor. The absence of Dox in the leg muscle
shows that the heating was restricted only to the tumor. There
was not a difference in tumor uptake of Dox under NT by any
of the formulations showing that targeting do not contribute to
increased drug uptake at this conditions. However, when initial
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HT for 1 h at 41°C was applied, there was an increased Dox
uptake in the tumor from both formulations, which is likely due
to increased extravasation of liposomes uponHT and therefore
their higher accumulation at the tumor site.
Future experiments will focus on improving the HT treat-
ment protocols and will address the efficacy of our dual
targeted and triggered drug delivery approach using cRGD
thermosensitive liposomes.
CONCLUSION
RGD-TSL encapsulating Dox were successfully developed
with both targeting and triggered properties. They demon-
strated specificity to tumor and endothelial cells as compared
to non-targeted TSL. RGD-TSL were taken up by acidic
compartments in cytosol and intracellularly released Dox up-
on HT. In vivo, RGD-TSL bound to angiogenic endothelial
cells and massively released Dox when HT was applied.
Biodistribution studies showed that initial HT treatment in-
creases Dox delivery to the tumor from both formulations.
Further studies will address the efficacy of our dual targeted
and triggered Dox delivery approach using RGD-TSL.
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